A Prescription Digital Therapeutic to Support Unsupervised Buprenorphine Initiation for Patients With Opioid Use Disorder: Protocol for a Proof-of-Concept Study.

Hilary Luderer¹, Nicole Enman¹, Robert Gerwien¹, Stephen Braun¹, Samantha McStocker¹, Xiaorui Xiong¹, Carrington Koebele², Christopher Cannon², Joseph Glass³, Yuri Maricich¹

¹Pear Therapeutics (US), Inc, Boston, MA, United States.

²Whitman-Walker Institute, Washington, DC, United States.

³Kaiser Permanente Washington Health Research Institute, Seattle, WA, United States.

PubMed PMC DOI PDF

Abstract

BACKGROUND: Home-based (unsupervised) buprenorphine initiation is considered safe and effective, yet many patients report barriers to successful treatment initiation. Prescription digital therapeutics (PDTs) are software-based disease treatments regulated by the US Food and Drug Administration (FDA). The reSET-O PDT was authorized by the FDA in 2018 and delivers behavioral treatment for individual…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Mentioned Companies

Pear Therapeutics
affiliation

NIH Funding

Grant #10153370
A game-based intervention for Opioid Use Disorder
PEAR THERAPEUTICS, INC.
$55,714 (FY2020)
Grant #9839289
A Prescription Digital Therapeutic to Promote Adherence to Buprenorphine Pharmacotherapy for Patients with Opioid Use Disorder
PEAR THERAPEUTICS, INC.
$214,833 (FY2019)

Other Funding

NIDA NIH HHS(R44 DA042652)
United States
NIDA NIH HHS(R44 DA049493)
United States

Keywords

OUDPDTbuprenorphinedigital health interventiondigital therapeuticsmedication adherenceopioid use disorderprescription digital therapeuticreSET-Ounsupervised buprenorphine initiation

Article Info

PMID: 36662568
PMCID: PMC9898828
DOI: 10.2196/43122
Received: September 30, 2022
Accepted: December 13, 2022

How to Cite

Luderer H et al. A Prescription Digital Therapeutic to Support Unsupervised Buprenorphine Initiation for Patients With Opioid Use Disorder: Protocol for a Proof-of-Concept Study. JMIR Res Protoc2023;12e43122. doi:10.2196/43122

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.